RBF Symposium Organizing Committee
Last Modified: January 17, 2013
Dates: February 4-6, 2013
Location: Zydus Research Center, Ahmedabad
Sponsoring Group: RBF Symposium Organizing Committee
Web Page URL: www.rbfsymposium.net
Topics Covered: Focus on Cancer, Pain, Inflammation, Cardio-metabolic, Infectious diseases.
Objectives: Key Features:
Who Should Attend: Industry, Academia
Agenda: Dear Colleagues It's our pleasure to welcome you to participate in the Ramanbhai Foundation 6th International Symposium on "Advances in New Drug Discovery Technologies And Translational Research" to be held in Ahmedabad, India from February 4-6, 2013, with a focus on cancer, pain, inflammation, cardio-metabolic and infectious diseases. The RBF Conference brings together biotechnology and pharmaceutical both from Industry and Academia from India, North America, Europe and the Asia-Pacific region. RBF Symposium has been recognized as a leading scientific and networking conference in Asia over the past many years with participants representing leading companies and academic institutes from around the world. Key Speakers include: - Dr. Peter Schultz, Director, Calibr Institute Professor of Chemistry, The Scripps Research Institute, USA - Dr. Steven G. Reed, Founder, President, Chief Scientific Officer, Infectious Disease Research Institute, USA - Dr. Ajoy Basak, Scientist, Chronic Disease, Ottawa Hospital Research Institute and Principle Investigator, Regional Protein Chemistry Centre, Canada - Dr. Alex Haahr Gouliaev, CEO, Nuevolution, Denmark - Dr. Anil Bhansali, Professor and Head, Department of Endocrinology, PGIMER, Chandigarh, India - Dr. Kapil Dhingra, KAPital Consulting, LLC, USA - Dr. Johanna Holldack, MD, Chief Executive Officer, Telormedix SA, Switzerland. - Dr. Lee Helman, Head Senior Investigator, Molecular Oncology Section, National Cancer Institute, USA - Dr. Purvish M. Parikh, Prof Head. Dept of Medical Oncology, Tata Memorial Hospital, India - Dr. Ranjan Mukherjee, Sr Principal Scientist, Cardiovascular Diseases Research, Bristol-Myers Squibb, USA - Dr. Samit Hirawat, Vice President, Oncology, Novartis, USA - Dr. Jan ter Meulen, Executive Director Vaccine Research, Merck Research Laboratories, USA - Dr. Stephen Yoder, CEO, Pieris AG, Germany more.
Registration Information: To register ONLINE for this conference, please visit, http://www.rbfsymposium.net/registration.asp EARLY REGISTRATION closes on December 31, 2012
Fees: USD 150-300
Continuing Education: No
Sep 24, 2014 - In acute lymphoblastic leukemia, tumor vulnerability to different chemotherapeutic agents varies at different stages of clonal evolution, which could represent a viable strategy in avoiding drug resistance. These findings were presented at the American Association for Cancer Research's special conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies, held from Sept. 20 to 23 in Philadelphia.